U.S. Markets open in 6 hrs 31 mins
  • S&P Futures

    4,250.25
    +4.50 (+0.11%)
     
  • Dow Futures

    34,496.00
    +34.00 (+0.10%)
     
  • Nasdaq Futures

    14,019.25
    +25.00 (+0.18%)
     
  • Russell 2000 Futures

    2,333.10
    +2.60 (+0.11%)
     
  • Crude Oil

    71.33
    +0.42 (+0.59%)
     
  • Gold

    1,862.40
    -17.20 (-0.92%)
     
  • Silver

    27.92
    -0.23 (-0.80%)
     
  • EUR/USD

    1.2108
    +0.0001 (+0.0121%)
     
  • 10-Yr Bond

    1.4620
    0.0000 (0.00%)
     
  • Vix

    15.65
    -0.45 (-2.80%)
     
  • GBP/USD

    1.4108
    -0.0008 (-0.0578%)
     
  • USD/JPY

    109.6800
    +0.0450 (+0.0410%)
     
  • BTC-USD

    39,599.62
    +4,322.19 (+12.25%)
     
  • CMC Crypto 200

    985.86
    +44.04 (+4.68%)
     
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Avrobio Inc (NASDAQ: AVRO) has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2 trial.

  • In March, the FDA granted full approval to Sanofi's SA (NASDAQ: SNY) Fabrazyme (agalsidase beta) after it received accelerated approval based on a surrogate endpoint of reduction of GL-3 inclusions in biopsied renal peritubular capillaries (PTCs).

  • The conversion of Fabrazyme to full approval limits the accelerated approval pathways available for new therapies to treat Fabry disease.

  • Hence, Avrobio can no longer pursue an accelerated approval pathway for AVR-RD-01 and instead plans to discuss with FDA a registration trial with a primary efficacy endpoint of clearance of GL-3/Gb3 inclusions in biopsied renal PTCs.

  • Registration trial is expected to initiate in mid-2022.

  • To support the use of AVR-RD-01 in a broad Fabry disease population, the company expects to include female patients, eliminate antibody status exclusions and collect additional cardiovascular and CNS data in its ongoing FAB-GT trial.

  • Price Action: AVRO shares are down 5.75% at $11.01 in the premarket trading on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.